Last update 01 Nov 2024

Ceolia Pharma Co., Ltd.

Private Company|
2010|
Tokyo-to, Japan
|
www.ceolia.co.jp

Overview

Tags

Otorhinolaryngologic Diseases
Other Diseases
Endocrinology and Metabolic Disease
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
Bacterial Top II(Bacterial topoisomerase II)1
CYP11B1(Steroid 11-beta-hydroxylase)1

Related

3
Drugs associated with Ceolia Pharma Co., Ltd.
Levofloxacin
Target
Bacterial Top II
Mechanism
Bacterial Top II inhibitors
Active Org.
CHIESI Farmaceutici SpACHIESI Farmaceutici SpA [+5]
Originator Org.
Johnson & JohnsonJohnson & Johnson
Active Indication
Otitis Externa [+31]
Inactive Indication
Abscess [+36]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date20 Dec 1996
Metyrapone
Target
CYP11B1
Mechanism
CYP11B1 inhibitors
Active Org.
HRA Pharma Development SARLHRA Pharma Development SARL [+4]
Originator Org.
Novartis SA
Active Indication
Adrenal Insufficiency [+2]
Inactive Indication
Endogenous Cushing Syndrome
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 Dec 1961
ENT-103
Target-
Mechanism-
Active Org.
NANO MRNA Co., Ltd.NANO MRNA Co., Ltd. [+1]
Originator Org.
Ceolia Pharma Co., Ltd.
Active Indication
Otitis Media
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with Ceolia Pharma Co., Ltd.
JPRN-jRCT2031240141 / RecruitingNot Applicable
General Drug Use-Results Survey of COMLEX OTIC SOLUTION 1.5%
JPRN-jRCTs031200058 / CompletedPhase 1IIT
Active-control,randomized, open-label controlled trial comparing the efficacy and safety of dioctyl sodium sulfosuccinate otic solution 5% CEO for navel dirt removal before abdominal surgery
JPRN-JapicCTI-194730 / CompletedPhase 3
ENT103 Phase 3 Clinical Study in Patients with Suppurative Otitis Media with Persistent or Prolonged Otorrhea
100 Clinical Results associated with Ceolia Pharma Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Ceolia Pharma Co., Ltd.
Login to view more data
100 Deals associated with Ceolia Pharma Co., Ltd.
Login to view more data
100 Translational Medicine associated with Ceolia Pharma Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3 Clinical
1
2
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Metyrapone
 ( CYP11B1 )		-
Approved
Levofloxacin
 ( Bacterial Top II )		Otitis Media
More
Approved
ENT-103
Otitis Media
More
Phase 3
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free